Show your work.
A reference is only as honest as its citations. So every monograph links each claim to the primary source — the FDA label, the trial registration, the docket, the paper — for you to check yourself. No “trust us.” Here’s exactly how the catalog is sourced, what we verify against, and what re-checking has corrected.
Time-sensitive claims — approval, dosing, legal status, trial state — are verified against the authorities below, not against vendor copy. Each links to its home.
On every monograph, each source carries a type badge and a one-line note on what it underpins. Primary sources lead; secondary context is labelled, never disguised.
The FDA-approved prescribing label (via NLM DailyMed / Drugs@FDA) — the authoritative dosing and safety text. Only exists for approved drugs.
A registered trial with its design, status, and any posted results. The registry entry, not a press release about it.
The 503A/503B compounding record and PCAC review on regulations.gov — where a compound's legal status actually lives.
A primary study or review in the indexed literature, opened as a PubMed search on the citation so you land on the paper itself.
Market context, company releases, or trade coverage. Useful, but not primary — flagged as such, and pointed at the underlying registry where one exists.
Every profile was built by one researcher, then adversarially re-checked by another focused on numbers, dates, dosing math, and legal status. That catches real errors. When it does, we change the catalog and say so — here’s the standing record.
- 01Tirzepatide oral-contraceptive Cmax drop is ~55-66% (not ~50%).
- 02Anesthesia/aspiration guidance: cite the Oct-2024 multisociety guidance, not the superseded Jun-2023 ASA press release.
- 03Add Selank/Semax x serotonergic agents (SSRI/SNRI/MAOI) as a low-confidence serotonin-syndrome CAUTION.
- 04Selank was NOT removed in the Apr 2026 wave and is NOT 'Category 1' - vendor claims to the contrary are false.
- 05Full 122-record interaction matrix lives in research/iteration4.json.
This field moves monthly. Anything about compounding legality, quarterly sales, or trial status is stale by default — re-verify against the primary source (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting. Catalog last reviewed end-to-end June 2026.
The full index — each compound’s primary citations, with the last date it was verified. Open any monograph for the claim-by-claim context.
Not medical or legal advice. Links open primary registries in a new tab; we can’t control their contents. Re-verify against the primary source before acting.